A Case of Chronic Graft-versus-Host-Disease Following Allogeneic Peripheral Blood Stem Cell Rescue for Poor Graft Function after Bone Marrow Transplantation

Hyeoung Joon Kim, M.D., Ik Joo Chung, M.D., Je Jung Lee, M.D., Jae Sung Seo, M.D., Moo Rim Park, M.D., Kyeoung Sang Choi, M.D., Hoon Kook, M.D.,* Tai Ju Hwang, M.D.*

Departments of Internal Medicine and Pediatrics*, BMT Program, Chonnam University Medical School, Kwangju, Korea

To overcome poor graft function after allogeneic bone marrow transplantation (BMT), the use of peripheral blood stem cells (PBSC) instead of bone marrow is gaining more popularity because of its advantages. There may, however, be an increased risk of graft-versus-host-disease (GVHD) because of the large number of lymphocytes present in a leukapheresis product.

An 18-year-old man with severe aplastic anemia underwent an allogeneic BMT using his HLA-identical sister. After initial excellent graft take for 8 months, his blood counts gradually decreased to 2.8 \times 10^9/L of white cells and 28 \times 10^9/L of platelets with marrow cellularity of <10%. After allogeneic granulocyte-colony stimulating factor mobilized PBSC rescue, the patient's blood counts recovered satisfactorily. Around 1 year after the boost, he developed chronic GVHD that responded to prednisolone and cyclosporin A. He is now well on low-dose steroids at day +1055 after PBSC rescue. The present case is the first experience of a long-term follow-up who underwent allogeneic PBSC rescue in Korea.

Key Words : Severe aplastic anemia; Bone marrow transplantation; Poor graft function; Peripheral blood stem cells; Graft-versus-host-disease

Recently, infusion of allogeneic peripheral blood stem cells (PBSC) mobilized by granulocyte-colony stimulating factor (G-CSF) has been used in patients with graft failure after allogeneic BMT\(^1\). Allogeneic PBSC transplantation has some advantages over allogeneic BMT: general anesthesia is not required to collect hematopoietic stem cells and faster hematologic recovery has been reported. There may, however, be an increased risk of graft-versus-host-disease (GVHD) as leukapheresis products usually contain 1 log higher T lymphocytes than bone marrow\(^2\). Here we report a case of a long-term follow-up who developed chronic GVHD following allogeneic PBSC rescue for poor graft function after allogeneic BMT.

CASE

An 18-year-old man with severe aplastic anemia, who
was diagnosed in June 1991, underwent an allogeneic BMT from his HLA-identical 21-year-old sister. The patient was positive for HBsAg and HBeAg, but liver enzymes were normal. The conditioning regimen consisted of procarbazine orally at a dose of 6.25 mg/kg/day for 3 days and cyclophosphamide at 50 mg/kg/day for 4 days and antithymocyte globulin at 1.25 mg/kg/day for 3 days. A conventional regimen of short course methotrexate and cyclosporin A (CSA) was used for the prophylaxis of GVHD. Engraftment (ANC > 500 X 10⁶/L) was documented on day +14. The early post-BMT period was uneventful without the evidence of acute GVHD. After initial excellent graft take for 8 months, his blood counts gradually decreased to 2.8 X 10⁹/L of white cells and 28 X 10⁹/L of platelets. The marrow cellularity was < 10%. There was no infectious evidence including cytomegaloviral infection or acute exacerbation of hepatitis B responsible for marrow suppression. DNA finger printing, using variable-number-of-tandem-repeats (VNTR), revealed a donor engraftment. Recombinant human granulocyte macrophage-colony stimulating factor (GM-CSF) at 5 μg/kg/day was tried for three weeks to no avail. After obtaining informed consents from both donor and recipient, we proceeded to allogeneic transplantation with PBPC mobilized with G-CSF. The donor received filgrastim at a dose of 5 μg/kg/day subcutaneously for 7 consecutive days. On day 8, the donor underwent a 7 L leukapheresis with Fenwal CS-3000 plus cell separator. The donor had no side effects during PBSC mobilization and collection.

Fig. 1. Hematologic Parameters

On day 429 following BMT, a total of 1.6 X 10⁶/kg mononuclear cells and 4.3 X 10⁶/kg CD34+ cells was infused without further processing. Antilymphocyte globulin (10 mg/kg/day for 5 days) was used as a sole preparative therapy. As a GVHD prophylaxis, CSA was reinfused at 10 mg/kg. The patient's blood counts recovered satisfactorily after the boost (Fig. 1). Marrow aspirates on 26 days after boost showed 40% cellularity with trilineage engraftment. Full engraftment was achieved and he was monitored as

Fig. 2. Microscopic findings of GVHD of liver(A) and stomach(B, C). A. There are portal inflammatory infiltrates, bile duct damage with epithelial cell swelling and perivenular fibrosis. X400 (H&E). B, C. There are indistinct crypt abscess, apoptotic cells of mucosal glands, and dense inflammatory infiltration of lamina propria. X250, X400 (H&E)
an outpatient after discharge from hospital on day 31 after the boost.

Around 1 year after the boost (January 1995), while he was on oral CSA at 50 mg, he developed abdominal pain, diarrhea and jaundice. Blood counts were normal (Hgb 12.5 g/dL, WBC 7.2 X 10^9/L, platelet 125 X 10^9/L), but liver function tests were markedly abnormal (maximum total bilirubin 19.4 mg/dL; direct bilirubin 12.4 mg/dL; alkaline phosphatase 169 IU/L; AST 54 IU/L; ALT 70 IU/L). On the clinical ground, cytomegaloviral (CMV) enteritis and hepatitis, acute exacerbation of hepatitis B, or chronic GVHD, were suspected. CMV was excluded by negative early antigenemia assay, polymerase chain reaction and shell vial culture. A percutaneous liver biopsy specimen. He developed extensive chronic GVHD involving skin, eye, liver, oral and gastrointestinal mucosa. The pulse therapy of prednisolone 60 mg/day and CSA 600 mg/day resulted in gradual improvement of GVHD and he is now well on low-dose steroid at day +1055 after PBSC rescue.

**DISCUSSION**

Poor graft function, as indicated by a decrease in the peripheral blood counts to less than 40% of the maximal preceding values post-transplant, in association with reduced marrow cellularity, is an infrequent but serious complication of BMT. Therapy of poor graft function is not always successful with a second marrow infusion or, more recently, the administration of human recombinant growth factors (CSFs). In our case, recombinant human GM-CSF at 5 μg/kg/day was tried for three weeks to no avail. As the addition of CSF-mobilized peripheral blood progenitor cells (PBPC) to autologous bone marrow grafts markedly improves hematopoietic recovery, infusion of donor-derived PBSC may also help to overcome insufficient hematopoiesis after allogeneic BMT. The first report of PBSC for allogeneic transplantation was by Kessinger et al. They reported rapid tri-lineage engraftment using PBSC collected during steady-state hematopoiesis; however, a total of nine leukaphereses were required to obtain sufficient cells. Russell et al and Degeer et al used G-CSF mobilized PBSC for allogeneic transplantation. Both patients were reported to have sustained tri-lineage engraftment with good hematopoietic function.

The clinical advantages of PBSC transplants over BMT for allogeneic transplantation have been described in a number of studies. For the donor, the harvest can be performed without the need for a general anesthesia and avoids the usually minor but not negligible morbidity associated with BM harvesting. Modern automated continuous flow cell separators can process 9 L of blood in 3 h without the need for central vascular catheters, providing there is good venous access. G-CSF has a high safety profile with only minor side-effects.

For the recipient, potential advantages of the use of PBSC include accelerated neutrophil and platelet engraftment as has been documented following autologous PBSC. The high number of progenitor cells that can be harvested from G-CSF-mobilized peripheral blood may be particularly advantageous in transplantation for aplastic anemia where an increased risk of rejection has been associated with the infusion of less than 3 X 10^9 BM cells/kg.

Potential disadvantages of autologous PBSCT include the theoretical increased risk of GVHD due to the presence of approximately 1 log larger numbers of T lymphocytes in the leukapheresis products than in BM. Unexpectedly, however, incidence and severity of acute GVHD were not increased. Data on chronic GVHD with limited follow-up periods are controversial. However, tendency toward an increased incidence of chronic GVHD has been reported in some studies, correlating with T cell doses. The chronic form of GVHD seemed to be less sensitive to CSA given either prophylactically or therapeutically. Improvement in the prophylaxis and control of chronic GVHD, such as the addition of steroids or a partial T cell depletion, should be considered in case the chronic GVHD in autologous PBSC might affect the survival and performance adversely.

This case suggests that mobilized PBSCs are capable of providing a complete, sustained hematopoietic engraftment, and the use of primed PBSC for allogeneic transplantation is a feasible alternative to BM in treating poor graft function after BMT. Nevertheless, further studies are required to fully assess its pros and cons, particularly in terms of GVHD and survival.

**REFERENCES**

1. Nemunaitis J, Singer JW, Buckner CD, Dumam D, Epstein C, Hill R, Stoeh R, Thomas ED, Appelbaum FR. Use of recombinant human granulocyte-macrophage colony-stimulating factor in graft failure after bone marrow transplantation. Blood 1990; 76:245.
2. Dreger P, Suttorp M, Haferlach T, Loefler M, Schmiz N, Schroyens W: Allogeneic granulocyte colony-stimulating factor-mobilised peripheral blood progenitor cells for treatment of engraftment failure after bone marrow transplantation. Blood 1993; 81:1404.

3. Russell JA, Luider J, Weaver M, Brown C, Selinger S, Railton C, Karlsson L, Klassen J: Collection of progenitor cells for allogeneic transplantation from peripheral blood of normal donors. Bone Marrow Transplant 1995; 15:111.

4. Weaver CH, Longin K, Buckner CD, Bensinger W: Lymphocyte content in peripheral blood mononuclear cell collected after the administration of recombinant human granulocyte colony-stimulating factor. Bone Marrow Transplant 1994; 7:411.

5. Peralvo J, Bacigalupo A, Pittaluga PA, Occhini D, Van Lint MT, Frassoni F, Nardelli E, Transino A, Pantanotto M, Marmout AM: Poor graft function associated with graft-versus-host disease after allogeneic marrow transplantation. Bone Marrow Transplant. 1987; 2:279.

6. Kessinger A, Smith DM, Strandjord SF, Landmark JD, Dockey DC, Law P, Coccia PF, Warkentin PI, Weickenburger DD, Armitage JO: Allogeneic transplantation of blood-derived, T cell-depleted hematopoietic stem cells after myeloablatative treatment in a patient with acute lymphoblastic leukemia. Bone-Marrow-Transplant. 1989: 4:643.

7. Russell NH, Hunter AE, Rogers S, Hanley J, Anderson D: Peripheral blood stem cells for allogeneic transplantation. Lancet 1993; 341:1482.

8. Buckner CD, Clift RA, Sanders JE, Stewart P, Bensinger WI, Doney KC, Sullivan KM, Witherspoon RP, Deeg HJ, Appelbaum FR: Marrow harvesting from normal donors. Blood 1984; 64:630.

9. Niederwieser D, Pepe M, Storb R, Loughian TP, Lanton G: Improvement in rejection, engraftment and survival without increase in graft-versus-host disease by high marrow cell dose in patients transplanted for aplastic anemia Br J Haematol 1988; 69:23.

10. Majolin I, Saglio G, Scime’s R, Serra A, Cavallaro AM, Fiandaca T, Vasta S, Pampinella M, Catania P, Indovina R, Marcano R, Santoro A: High incidence of chronic GVHD after primary allogeneic peripheral blood stem cell transplantation in patients with hematologic malignancies. Bone Marrow Transplant 1996; 17:555.